Genomics of Immunotherapy-Associated Hyperprogressors-Response

Affiliations

¹ Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego Moores Cancer Center, San Diego, California. smkato@ucsd.edu.
² Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego Moores Cancer Center, San Diego, California.

Comment

Shumei Kato et al. Clin Cancer Res. 2017.

. 2017 Oct 15;23(20):6376.

doi: 10.1158/1078-0432.CCR-17-1990.

¹ Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego Moores Cancer Center, San Diego, California. smkato@ucsd.edu.
² Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego Moores Cancer Center, San Diego, California.

No abstract available

Comment on

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Kato S, et al. Clin Cancer Res. 2017 Aug 1;23(15):4242-4250. doi: 10.1158/1078-0432.CCR-16-3133. Epub 2017 Mar 28. Clin Cancer Res. 2017. PMID: 28351930 Free PMC article.
Genomics of Immunotherapy-Associated Hyperprogressors-Letter.
Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, Stenzinger A, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T. Forschner A, et al. Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480. Clin Cancer Res. 2017. PMID: 29030332 No abstract available.